NOVT Novanta

Research status: Primary-source verified through Novanta Q2 2026 results and Riverpoint Medical acquisition disclosures. Valuation basis: $145.24 close on 21 August 2026.

Novanta is one of the more interesting US-listed robotics picks-and-shovels because it sells precision motion, servo drives, sensing and other qualified components into automation while retaining a high-quality medical-technology base. Q2 2026 revenue was $265.8M, +10.3% reported and 9.3% organic; adjusted EBITDA was $60.7M, +16.4%, and operating cash flow was $64.9M. Management raised 2026 guidance to $1.13–1.14B revenue and $273–278M adjusted EBITDA.

The robotics evidence improved in Q2: management disclosed its first significant servo-drive orders supporting hundreds of humanoids in customer testing/training facilities, moving beyond pure prototype quantities. GenAI-linked applications represented about 17% of company revenue and grew roughly 25% YoY. This is still early evidence, not proof of commercial humanoid deployment.

Riverpoint Medical, completed in July, increases medical exposure to roughly 60% of revenue and approximately doubles recurring medical consumables to ~$300M annualized. That improves quality and recurring mix but makes acquisition integration/leverage part of the thesis. At $145.24, NOVT is a credible Robotics/AI diversifier with real cash generation; valuation and Riverpoint integration determine entry quality.

Investment case

Novanta supplies precision motion, encoders, servo drives, sensing, photonics and medical subsystems into equipment where qualification, calibration, safety and reliability create switching costs.

> The PowerFund thesis is that Novanta can compound as a high-quality enabling-component platform while robotics/humanoids create upside optionality through qualified motion and safety content. The base case does not require humanoids to become a major revenue category; the thesis strengthens materially if early training-center orders convert into serial production.

Verified operating baseline — Q2 2026

• Revenue: $265.8M, +10.3% reported / 9.3% organic.
• Adjusted EBITDA: $60.7M, +16.4%; margin 22.8%.
• Adjusted EPS: $0.89, +17.1%.
• Operating cash flow: $64.9M; YTD OCF $116.5M.
• New-product revenue grew >50% YoY.
• GenAI-linked applications: ~17% of revenue, growing ~25% YoY.
• Initial significant humanoid servo-drive orders: hundreds of units for testing/training facilities.

2026 guidance

• Revenue: $1.130–1.140B.
• Adjusted EBITDA: $273–278M.
• Adjusted EPS: $3.68–3.74.
• Q3 revenue: $300–304M including Riverpoint.

Riverpoint effect

• Raises medical end-market exposure to roughly 60%.
• Approximately doubles recurring medical consumables to ~$300M annualized.
• Expected by management to be accretive to growth, margins and EPS.

KPI ladder

PowerFund valuation scenarios

These are PowerFund estimates, not company guidance.

24 months

• Bear (20%) — $105–120: Riverpoint integration disappoints, organic growth slows and humanoid/AI demand remains immaterial.
• Base (55%) — $165–195: 7–9% organic growth, strong medical consumables, EBITDA margin expansion and modest robotics upside.
• Bull (25%) — $240–290: humanoid/automation orders scale into production while Riverpoint strengthens recurring earnings quality.

Probability-weighted midpoint is roughly $165–190/share.

60 months

• Bear: $120–150.
• Base: $260–350 as a diversified precision/medical technology compounder.
• Bull: $450–600+ if robotics/Physical AI becomes a material high-margin second growth engine.

• Humanoid servo-drive orders progressing from training centers to commercial deployments.
• Robotics/automation growth sustaining >15–20%.
• GenAI-linked revenue continuing ~20%+ growth.
• Riverpoint integration lifting recurring revenue and margins.
• Organic growth staying high-single digits.
• New-product vitality and design wins remaining strong.
• Deleveraging after Riverpoint while maintaining strong FCF.

• Humanoid timing: current orders are training/development, not evidence of mass commercial deployment.
• Acquisition integration: Riverpoint is Novanta's largest acquisition and changes mix/leverage materially.
• Valuation: quality premium can compress if organic growth slows.
• Semicap cyclicality: part of the automation/precision portfolio is exposed to equipment cycles.
• Customer/OEM design-in risk: platform loss can remove content for years.
• GAAP/adjusted gap: acquisition amortization and adjustments should be monitored.
• Robotics competition: component categories can face specialized global competitors.
• Medical concentration: post-Riverpoint exposure rises substantially.

Warning — freeze additions

• Organic growth <5% for two quarters.
• Book-to-bill <1x twice.
• Adjusted EBITDA margin <22% after Riverpoint integration period.
• Robotics/GenAI-linked growth drops below ~10% before commercialization broadens.
• Post-deal leverage fails to decline.

Reduce

• Riverpoint misses growth/margin accretion expectations materially.
• Key robotics OEM design-ins are lost.
• OCF materially lags adjusted EBITDA for multiple quarters.
• Humanoid program evidence remains stagnant for 6–8 quarters while valuation embeds large optionality.

Invalidate

> Invalidate if Novanta loses its high-quality component-compounder economics—weak organic growth, declining design-win momentum, poor Riverpoint integration and no credible return on acquisition capital.

Humanoid disappointment alone does not invalidate the base thesis unless valuation and core growth simultaneously weaken.

Novanta competes across specialized precision-motion, sensing, photonics and medical components. Qualification into OEM platforms creates switching costs because redesign affects mechanical integration, controls, calibration and regulatory/safety validation.

The deepest global robotics component franchises include Japanese motion/gear/sensing suppliers, but NOVT offers a practical US-listed expression with diversified cash-generative businesses. Its potential Physical-AI moat is qualified content per robot, not ownership of the robot platform.

1. Quantify Riverpoint purchase price, debt funding and post-deal net leverage.
2. Track humanoid servo-drive order value, customer count and transition from training to commercial use.
3. Separate robotics/GenAI-linked revenue from semicap exposure.
4. Reconcile GAAP EPS with acquisition amortization/adjusted EPS.
5. Track design wins and new-product vitality quarterly.
6. Compare NOVT's robotics exposure and valuation with AMBA, TER and industrial automation peers.
7. Build explicit valuation zones once Riverpoint's first full-quarter economics are reported.

Next full review: after Q3 2026 results / first full Riverpoint quarter.